NCT02626312 2026-04-16
Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
2,447 trialsNCT03259867 2026-04-16
TATE-PD1
Teclison Ltd.
Phase 2 Recruiting
NCT05842174 2026-04-16
TAQE
VA Office of Research and Development
Phase 1/2 Recruiting
NCT06066138 2026-04-16
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT07476651 2026-04-16
LASER
Seoul National University Hospital
Phase NA Recruiting
NCT07490262 2026-04-16
A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Phase 2/3 Recruiting
NCT03778957 2026-04-15
EMERALD-1
AstraZeneca
Phase 3 Active not recruiting
NCT04785534 2026-04-15
Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT05394259 2026-04-15
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT06427941 2026-04-15
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT06764316 2026-04-15
BANTAM-01
Bayer
Phase 1 Recruiting
NCT06968195 2026-04-15
Autologous CAR T Cells Targeting GPC3 (RPCAR01) for the Treatment of Advanced or Metastatic GPC3 Expressing Hepatocellular Carcinoma
Roswell Park Cancer Institute
Phase 1 Suspended
NCT03520660 2026-04-14
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
National Institutes of Health Clinical Center (CC)
Phase 4 Active not recruiting
NCT05435014 2026-04-14
T-ACE Oil by TAE/TACE in Patients With Hepatocellular Carcinoma
T-ACE Medical Co., Ltd
Phase 1/2 Suspended
NCT06880523 2026-04-14
SLIDE-HCC
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07164313 2026-04-14
A Study of ZW251 in Participants With Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1 Recruiting
NCT07291076 2026-04-14
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT02465060 2026-04-13
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02771405 2026-04-13
FRI-STC
National Hepatology & Tropical Medicine Research Institute
Phase 3 Completed
NCT02772003 2026-04-13
DNA Vaccine Therapy in Treating Patients With Chronic Hepatitis C Virus Infection
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02867592 2026-04-13
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT02968810 2026-04-13
Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05257590 2026-04-13
CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Recruiting
NCT06086002 2026-04-13
Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular Carcinoma
Seoul National University Hospital
Phase NA Completed
NCT06362369 2026-04-13
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
Phase 1/2 Recruiting
NCT06426992 2026-04-13
Clinical Effectiveness of Microwave Ablation Using Starwave Microwave Generator for Hepatic Malignancies
Seoul National University Hospital
Phase NA Recruiting
NCT06582017 2026-04-13
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Nammi Therapeutics Inc
Phase 1 Recruiting
NCT06679985 2026-04-13
A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Coherus Oncology, Inc.
Phase 2 Active not recruiting
NCT06726161 2026-04-13
GPC3
RayzeBio, Inc.
Phase 1/2 Recruiting
NCT06811116 2026-04-13
Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06938945 2026-04-13
Electronic Symptom Monitoring of Patient-Reported Outcomes Among Patients With Hepatocellular Carcinoma During Immunotherapy (PRIME-HCC): Protocol for a Randomised Controlled Trial
Peking University
Phase NA Recruiting
NCT06995898 2026-04-13
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
Phase NA Recruiting
NCT07192172 2026-04-13
ERFA
Seoul National University Hospital
Phase NA Completed
NCT07521852 2026-04-13
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC
TaiRx, Inc.
Phase 2 Recruiting
NCT07522411 2026-04-13
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
Tongji Hospital
Phase 1/2 Not yet recruiting
NCT07523529 2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2 Recruiting
NCT04180072 2026-04-09
Atezolizumab Plus Bevacizumab With HCC and HBV Infection
National Health Research Institutes, Taiwan
Phase NA Active not recruiting
NCT05858736 2026-04-09
PRESERVE-009
OncoC4, Inc.
Phase 1 Active not recruiting
NCT05919264 2026-04-09
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Parabilis Medicines, Inc.
Phase 1/2 Recruiting
NCT07293468 2026-04-09
BIIRTH
Tuen Mun Hospital
Phase 2/3 Recruiting
NCT07419841 2026-04-09
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Compass Therapeutics
Phase 1 Recruiting
NCT07518706 2026-04-09
Neoadjuvant Tislelizumab-Lenvatinib vs Surgery Alone in Stage Ia HCC With Narrow Margin
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT07227012 2026-04-08
Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
Phase 1/2 Recruiting
NCT05003895 2026-04-07
GPC3 Targeted CAR-T Cell Therapy in Advanced GPC3 Expressing Solid Tumor Malignancies
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT05301842 2026-04-07
EMERALD-3
AstraZeneca
Phase 3 Active not recruiting
NCT07514429 2026-04-07
RELEVANT-HCC
Asan Medical Center
Phase 2 Not yet recruiting
NCT07514455 2026-04-07
RECOMEND
Asan Medical Center
Phase 2 Not yet recruiting
NCT07515469 2026-04-07
A Prospective, Single-Arm, Exploratory Study of the Safety and Efficacy of Neoadjuvant Treatment With QL1706, an Anti-PD-1/Anti-CTLA-4 Bispecific Antibody, in Resectable Stage IB and IIA Hepatocellular Carcinoma With High Recurrence Risk
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting